Influenza virus‐like particles engineered by protein transfer with tumor‐associated antigens induces protective antitumor immunity

Patel, Jaina; Vartabedian, Vincent F.; Kim, Min‐Chul; He, Sara; Kang, Sang‐Moo; Selvaraj, Periasamy

doi:10.1002/bit.25537

Cited by 41 publications

(46 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the latter treatment failed to confer significant protection against tumor challenge, indicating that the cellular immunity must play a major role. This correlated well with Th1-skewed immune response observed in the study (Patel et al 2015b). Her2 is a novel TAA, which is also overexpressed in many different cancers, such as endometrial carcinoma, gastric cancer, salivary duct carcinoma, lungs adenocarcinoma, and ovary cancer (Chiosea et al 2015;Meza-Junco et al 2011;Ruschoff et al 2012;Santin et al 2008).…”

Section: Breast Cancersupporting

confidence: 90%

“…In addition, attributed to the viral origin of VLPs, some of the VLP-based vaccines are self-adjuvating, in which, they contain the pathogen associated molecular pattern (PAMP) of viruses that could potentially enhance the activation of innate immune systems via the Toll-like receptors and pattern recognition receptors (Crisci et al 2012;Rynda-Apple et al 2014). These self-assembling, engineerable, and safe VLPs can be leveraged to display various tumor antigens for targeting different cancers (Patel et al 2015a;Patel et al 2015b). Genetic fusion of a tumor antigen to a non-self-antigen, such as a virus coat protein, was previously reported to notably improve its immunogenicity (Savelyeva et al 2001).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Peer Review #3 of "Virus like particles as a platform for cancer vaccine development (v0.2)"

2017

View full text Add to dashboard Cite

Cancers have killed millions of people in human history and are still posing a serious health problem worldwide. Therefore, there is an urgent need for developing preventive and therapeutic cancer vaccines. Among various cancer vaccine development platforms, viruslike particles (VLPs) offer several advantages. VLPs are multimeric nanostructures with morphology resembling that of native viruses and are mainly composed of surface structural proteins of viruses but are devoid of viral genetic material rendering them neither infective nor replicative. In addition, they can be engineered to display multiple highly ordered heterologous epitopes or peptides in order to optimize the antigenicity and immunogenicity of the displayed entities. Like native viruses, specific epitopes displayed on VLPs can be taken up, processed, and presented by antigen-presenting cells to elicit potent specific humoral and cell-mediated immune responses. Several studies also indicated that VLPs could overcome the immunosuppressive state of the tumor microenvironment and break self-tolerance to elicit strong cytotoxic lymphocyte activity, which is crucial for both virus clearance and destruction of cancerous cells. Collectively, these unique characteristics of VLPs make them optimal cancer vaccine candidates. This review discusses current progress in the development of VLP-based cancer vaccines and some potential drawbacks of VLPs in cancer vaccine development. Extracellular vesicles with close resembling to viral particles are also be discussed and compared with VLPs as a platform in cancer vaccine developments.

show abstract

Section: Breast Cancersupporting

confidence: 90%

mentioning

confidence: 99%

Peer Review #3 of "Virus like particles as a platform for cancer vaccine development (v0.2)"

2017

View full text Add to dashboard Cite

show abstract

“…The GPI-HER-2 DNA construct was constructed as previously described (24). Mouse GPI-B7-1 was constructed by attaching the CD59 GPI-signal sequence nucleotides to the extracellular domain of mouse B7-1 (GenBank BC131959.1, nucleotides 45–800) via an EcoRI restriction enzyme site.…”

Section: Methodsmentioning

confidence: 99%

“…The GPI-anchored proteins (GPI-APs) were purified from lysates of CHO-K1 cell transfectants by affinity chromatography as previously described (17, 20, 24). GPI-HER-2 and GPI-B7-1 were eluted from the mAb-affinity chromatography column using 100mM Triethylamine, 1% n-octyl-β-D-glucopyranoside, pH 11.6, and GPI-IL-12 was eluted using 100 mM Glycine-HCl pH 2.8 containing 1% n-octyl-β-D-glucopyranoside, and 10 mM sodium iodoacetate.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Plasma membrane vesicles decorated with glycolipid-anchored antigens and adjuvants via protein transfer as an antigen delivery platform for inhibition of tumor growth

et al. 2016

Self Cite

View full text Add to dashboard Cite

Antigen delivered within particulate materials leads to enhanced antigen-specific immunity compared to soluble administration of antigen. However, current delivery approaches for antigen encapsulated in synthetic particulate materials are limited by the complexity of particle production that affects stability and immunogenicity of the antigen. Herein, we describe a protein delivery system that utilizes plasma membrane vesicles (PMVs) derived from biological materials such as cultured cells or isolated tissues and a simple protein transfer technology. We show that these particulate PMVs can be easily modified within 4 h by a protein transfer process to stably incorporate a glycosylphosphatidylinositol (GPI)-anchored form of the breast cancer antigen HER-2 onto the PMV surface. Immunization of mice with GPI-HER-2-modified-PMVs induced strong HER-2-specific antibody responses and protection from tumor challenge in two different breast cancer models. Further incorporation of the immunostimulatory molecules IL-12 and B7-1 onto the PMVs by protein transfer enhanced tumor protection and induced beneficial Th1 and Th2-type HER-2-specific immune responses. Since protein antigens can be easily converted to GPI-anchored forms, these results demonstrate that isolated plasma membrane vesicles can be modified with desired antigens along with immunostimulatory molecules by protein transfer and used as a vaccine delivery vehicle to elicit potent antigen-specific immunity.

show abstract

Development and application of reverse genetic technology for the influenza virus

Zhong

et al. 2021

Virus Genes

View full text Add to dashboard Cite

Influenza virus is a common virus in people's daily lives, and it has certain infectivity in humans and animals. Influenza viruses have the characteristics of a high mutation rate and wide distribution. Reverse genetic technology is primarily used to modify viruses at the DNA level through targeted modification of the virus cDNA. Genetically modified influenza viruses have a unique advantage when researching the transmission and pathogenicity of influenza. With the continuous development of oncolytic viruses in recent years, studies have found that influenza viruses also have certain oncolytic activity. Influenza viruses can specifically recognize tumor cells; activate cytotoxic T cells, NK cells, dendritic cells, etc.; and stimulate the body to produce an immune response, thereby killing tumor cells. This article will review the development and application of influenza virus reverse genetic technology.

show abstract

Influenza virus‐like particles engineered by protein transfer with tumor‐associated antigens induces protective antitumor immunity

Cited by 41 publications

References 55 publications

Peer Review #3 of "Virus like particles as a platform for cancer vaccine development (v0.2)"

Peer Review #3 of "Virus like particles as a platform for cancer vaccine development (v0.2)"

Plasma membrane vesicles decorated with glycolipid-anchored antigens and adjuvants via protein transfer as an antigen delivery platform for inhibition of tumor growth

Development and application of reverse genetic technology for the influenza virus

Contact Info

Product

Resources

About